Stockscreener 앱 받기
5.69
0.52%
-0.03
시장 영업 전:
5.70
0.010
+0.18%
전일 마감가:
$5.72
열려 있는:
$5.72
하루 거래량:
478.95K
Relative Volume:
0.76
시가총액:
$539.87M
수익:
-
순이익/손실:
$-68.65M
주가수익비율:
-4.7743
EPS:
-1.1918
순현금흐름:
$-64.93M
1주 성능:
-0.18%
1개월 성능:
-7.78%
6개월 성능:
+53.37%
1년 성능:
+399.12%
1일 변동 폭
$5.60
$5.87
1주일 범위
$5.495
$5.88
52주 변동 폭
$0.98
$7.44
Zura Bio Ltd Stock (ZURA) Company Profile
명칭
Zura Bio Ltd
전화
858-247-0520
주소
4225 EXECUTIVE SQUARE, LA JOLLA
Compare ZURA vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ZURA
Zura Bio Ltd
|
5.69 | 542.72M | 0 | -68.65M | -64.93M | -1.1918 |
VRTX
Vertex Pharmaceuticals Inc
|
441.70 | 113.01B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
753.93 | 79.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
840.87 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
333.39 | 45.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
319.94 | 34.41B | 5.36B | 287.73M | 924.18M | 2.5229 |
Zura Bio Ltd Stock (ZURA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-09 | 개시 | Wedbush | Outperform |
| 2024-11-04 | 개시 | Leerink Partners | Outperform |
| 2024-09-05 | 개시 | H.C. Wainwright | Neutral |
| 2024-05-03 | 개시 | Piper Sandler | Overweight |
| 2023-10-10 | 개시 | Ladenburg Thalmann | Buy |
| 2023-08-25 | 개시 | Oppenheimer | Outperform |
| 2023-06-22 | 개시 | Guggenheim | Buy |
| 2023-06-14 | 개시 | Chardan Capital Markets | Buy |
| 2023-05-24 | 개시 | Raymond James | Strong Buy |
모두보기
Zura Bio Ltd 주식(ZURA)의 최신 뉴스
Zura Bio Ltd stock (KYG989201089): Is its immunology pipeline strong enough to unlock biotech upside - AD HOC NEWS
Zura Bio Ltd stock: Why analysts see massive upside potential - AD HOC NEWS
Biotechnology executive pays $15 million for Pinecrest home (Photos) - The Business Journals
Zura Bio (ZURA) CTO awarded 263,000 share options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) officer receives 340,900 options at $6.03 strike price - Stock Titan
Zura Bio (ZURA) CFO receives stock options for 340,900 shares at $6.03 - Stock Titan
Zura Bio grants 425,700 options to legal chief | ZURA Insider Trading - Stock Titan
Zura Bio (ZURA) CEO awarded options on 894,000 Class A shares - Stock Titan
Chipmakers Recap: Is Zura Bio Limited a momentum stock2026 Highlights & Verified Swing Trading Watchlist - baoquankhu1.vn
Market Fear: Will Zura Bio Limited benefit from rising consumer demandChart Signals & Risk Controlled Swing Trade Alerts - baoquankhu1.vn
Zura Bio (NASDAQ:ZURA) Price Target Raised to $11.00 at Chardan Capital - Defense World
Zura Bio Ltd reports results for the quarter ended December 31Earnings Summary - tradingview.com
ZURA: Chardan Capital Maintains 'Buy' Rating and Raises Price Ta - gurufocus.com
Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00 - Defense World
ZURA: Oppenheimer Lowers Price Target, Maintains Outperform Rati - GuruFocus
Zura Bio (NASDAQ:ZURA) Given New $15.00 Price Target at Oppenheimer - MarketBeat
Zura Bio Ltd expected to post a loss of 18 cents a shareEarnings Preview - TradingView
Zura Bio Limited (NASDAQ:ZURA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Zura Bio Ltd Aktie surges on positive Phase 2 data for autoimmune drug candidate - AD HOC NEWS
Zura Bio Limited 2025 Annual Report: Clinical-Stage Biotech Advancing Novel Autoimmune Therapies and Key Risk Factors - Minichart
Zura Bio (NASDAQ: ZURA) outlines autoimmune pipeline, Phase 2 timelines - Stock Titan
Zura Bio GAAP EPS of -$1.06 misses by $0.31 - One News Page
Zura Bio 10-K: $0.0M Revenue, $(X.XX) EPS on reported net loss - TradingView
2025 financial update released as Zura Bio outlines new corporate developments - Traders Union
Zura Bio (NASDAQ: ZURA) raises cash to fund Phase 2 trials - Stock Titan
Zura Bio Reports Full Year 2025 Financial Results and Recent Corporate Updates - ChartMill
Ajay Nirula Net Worth (2026) - GuruFocus
Jessica Chen - White & Case LLP
Boothbay Fund Management LLC Acquires New Shares in Zura Bio Limited $ZURA - MarketBeat
Zura Bio Limited (NASDAQ:ZURA) Short Interest Up 16.2% in February - MarketBeat
Zura Bio Limited $ZURA Stock Holdings Boosted by Suvretta Capital Management LLC - MarketBeat
ZURA Technical Analysis & Stock Price Forecast - Intellectia AI
Atika Capital Management LLC Takes Position in Zura Bio Limited $ZURA - Defense World
Zura Bio’s Tibulizumab: First-in-Class Bispecific Antibody Targeting IL-17 and BAFF for Autoimmune Diseases (HS & SSc) – Pipeline, Trials, and Market Opportunity 2348 - Minichart
Zura Bio Updates Corporate Outlook on Lead Tibulizumab Program - TipRanks
Zura Bio updates corporate presentation, flags tibulizumab Phase 2 readouts, cash and shares - TradingView
Updated investor presentation furnished by Zura Bio (NASDAQ: ZURA) - Stock Titan
ZURA Stock Price, Quote & Chart | ZURA BIO LTD (NASDAQ:ZURA) - ChartMill
Zura Bio presents Phase 2 systemic sclerosis trial design By Investing.com - Investing.com Australia
Zura Bio presents Phase 2 systemic sclerosis trial design - Investing.com South Africa
Zura Bio launches Phase 2 TibuSURE trial in systemic sclerosis at Athens congress - Traders Union
Zura Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic Sclerosis World Congress - weeklyvoice.com
Director at Zura Bio (ZURA) awarded 37,812 share options - Stock Titan
Major Zura Bio (ZURA) holder acquires 2M shares in registered deal - Stock Titan
Access Industries group lifts Zura Bio (ZURA) stake to 18.2% - Stock Titan
12 Health Care Stocks Moving In Monday's After-Market Session - Benzinga
Zura Bio heads to Miami for March 10-11 investor conferences - Stock Titan
Zura Bio raises $144 million in public offering of shares By Investing.com - Investing.com South Africa
Zura Bio raises $144 million in public offering of shares - Investing.com India
Zura Bio Announces Closing of its $144 Million Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares - ChartMill
Zura Bio (ZURA) revises Ogier legal opinion and consent in 8-K/A - Stock Titan
Zura Bio Ltd (ZURA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.69%
0.25%
자본화:
|
볼륨(24시간):